UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best affordable biotech stocks to invest in now. On September 12, UBS analyst Ashwani Verma maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $50.00.

Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported its fiscal Q2 2025 results on August 5, with its WAKIX franchise continually delivering strong growth with net revenue of $200.5 million for the quarter, up 16% year-over-year.

The company also announced the initiation of next-generation Pitolisant HD Phase 3 registration trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025, with both indications targeted for PDUFA in 2028.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders.

Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.

While we acknowledge the potential of HRMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HRMY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.